Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F13A1 | P00488 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | TGM1 | P22735 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 2/20 | 0.35 |
| ▸ | AR | P10275 | 2/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30635735 | 1.00 | F13A1 (0.45) | F13A1TGM2TGM1HSD11B1GPR119 | |
| SCHEMBL30635739 | 0.85 | HSD11B1 (0.46) | F13A1TGM2TGM1HSD11B1GPR119 | |
| SCHEMBL30411472 | 0.85 | HSD11B1 (0.46) | F13A1TGM2TGM1HSD11B1GPR119 | |
| SCHEMBL26629221 | 0.85 | CHRNB2 (0.35) | ALDH1A1MAPT | |
| SCHEMBL25215803 | 0.85 | CHRNB2 (0.35) | ALDH1A1MAPT | |
| SCHEMBL30411352 | 0.83 | HSD11B1 (0.45) | F13A1TGM2TGM1HSD11B1GPR119 | |
| SCHEMBL30126003 | 0.83 | RET (0.45) | F13A1TGM2TGM1HSD11B1GPR119 | |
| SCHEMBL11920568 | 0.82 | HSD11B1 (0.43) | F13A1TGM2TGM1HSD11B1GPR119 | |
| Bicarbonate SCHEMBL30412048 | 0.81 | HSD11B1 (0.43) | F13A1TGM2TGM1HSD11B1GPR119 | |
| SCHEMBL2718590 | 0.80 | MAPT (0.54) | F13A1TGM2TGM1HSD11B1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4433059-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | Erasca, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| WO-2023215494-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023087027-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ULK1, ULK2, ULK3 | F13A1 4774/4885TGM2 541/4885TGM1 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.